

Application of Biosensors for Real-Time Disease Detection

Rishab Sen^{1*}, Mitali Verma^{2*}, Aarav Pradhan^{3*}

¹School of Bio Technology, Galgotias University, Uttar Pradesh, India

²Engineering and Biosciences, Sharda University, Uttar Pradesh, India

³Department of Life Sciences, Lovely Professional University, Punjab, India

*Authors Email: rishab.sen@galgotias.edu.in, mitaliv@shardabiotech.edu.in, aarav.p@lpu.bio

Received:
Jan 22, 2024
Accepted:
Jan 23, 2024
Published online:
Jan 25, 2024

Abstract: The rapid global spread of infectious and chronic diseases has highlighted the urgent need for diagnostic technologies capable of delivering accurate, real-time data at the point of care. Biosensors, which integrate biological recognition systems with physicochemical transducers, have therefore emerged as indispensable tools in modern biomedicine. This paper offers a comprehensive examination of biosensor platforms used for real-time disease detection, emphasizing their operational mechanisms, technological evolution and clinical applications. Recent advances in nanomaterials, microfluidic engineering and synthetic biology have substantially enhanced biosensor sensitivity, selectivity and miniaturization, allowing detection of biomarkers at femtomolar concentrations. Wearable and implantable biosensors further extend diagnostic capabilities by enabling continuous physiological monitoring. The increasing integration of biosensors with wireless communication technologies and AI-driven analytics has opened new possibilities for personalized medicine and remote healthcare. Despite these advances, challenges persist regarding stability, biocompatibility, data security and regulatory approval. This study synthesizes state-of-the-art literature while identifying future directions such as multiplexed biosensing, bioelectronic medicine and digital-twin-assisted diagnostics. The analysis concludes that biosensors will continue to redefine medical diagnostics by enabling proactive, data-driven and precision-oriented healthcare systems.


Keywords: Biosensors, Real-Time Detection, Biomarkers, Diagnostics, Point-of-Care

1. Introduction

The acceleration of global disease burdens and the heightened risk of pandemics have intensified the demand for rapid, reliable and portable diagnostic systems. Traditional laboratory-based assays, including ELISA, PCR and microbial culture techniques, although highly accurate, require significant processing time, skilled personnel and sophisticated laboratory infrastructure. These limitations became especially evident during the COVID-19 pandemic, where delays in centralized testing hampered containment efforts worldwide. In contrast, biosensors offer real-time, on-site diagnostic capabilities with minimal operational complexity, making them crucial tools for timely medical decision-making [1]. Biosensors detect specific biomarkers such as nucleic acids, proteins, metabolites or pathogens and convert biological interactions into quantifiable signals. Their capacity for rapid signal transduction, miniaturization and integration with digital systems has enabled a paradigm shift toward decentralized healthcare [2]. Over the past decade, innovations such as nanostructured electrodes, microfabrication, CRISPR-based detection strategies and AI-assisted data interpretation have significantly improved accuracy and ease of deployment. Real-time disease detection is no longer a technical aspiration but an operational necessity. This paper explores biosensor fundamentals, emerging technologies and translational opportunities across healthcare sectors.

2. Biosensing Principles and System Architecture

A biosensor consists of three core components: a biorecognition element, a transducer and a signal-processing unit. Biorecognition elements including enzymes, antibodies, nucleic acid probes, aptamers and synthetic receptors enable selective binding to the target analyte [3]. Enzyme-based sensors were historically dominant, beginning with Clark and Lyons' glucose biosensor in 1962 [4]. Contemporary advancements, however, increasingly rely on DNA aptamers, CRISPR-associated systems and molecularly imprinted polymers for superior specificity and tunability. The transducer converts biological interactions into measurable signals. Electrochemical transducers remain widely used due to low cost and high sensitivity. Optical transducers particularly surface plasmon resonance and fluorescence resonance energy transfer—achieve ultra-low detection limits suitable for early disease diagnostics [5]. Mechanical transducers based on microcantilevers detect mass changes associated with molecular binding in real time. Signal processing, often enhanced by integrated circuits or cloud-linked systems, refines raw data into clinically meaningful outputs. With the expansion of IoT ecosystems, biosensor data can be streamed to smartphones, telemedicine platforms or hospital servers [6].



vallway.org

Fig. 1 Bio Sensing Principles

3. Detection Modalities and Technological Variants

Electrochemical biosensors dominate commercial markets due to their robustness and affordability. They measure changes in current, impedance or potential resulting from biochemical interactions. Glucose sensors remain the most commercially successful example, supported by decades of optimization and FDA approval [7]. Optical biosensors, particularly those based on plasmonics, fluorescence and Raman spectroscopy, provide label-free detection and ultra-high sensitivity. Surface-enhanced Raman scattering (SERS) platforms using gold or silver nanostructures have demonstrated detection of viral particles at picomolar levels [8]. Mechanical biosensors, including piezoelectric quartz crystal microbalances and nanocantilevers, detect mass fluctuations with remarkable precision. These devices are widely used for real-time kinetics studies and high-throughput biomarker screening [9]. Recent innovations include CRISPR-Cas-powered biosensors such as SHERLOCK and DETECTR, which have revolutionized nucleic acid detection through programmable target recognition and collateral cleavage reactions [10].

4. Real-Time Detection: Clinical Relevance and Mechanistic Demands

Real-time disease detection offers significant clinical advantages, such as immediate therapeutic decision-making, rapid outbreak response and personalized monitoring of disease progression. Biosensors with real-time capabilities must demonstrate high stability, rapid response times and consistent calibration across complex

physiological environments [11]. Wearable patches capable of tracking glucose, lactate or cortisol levels demonstrate how continuous monitoring can transform disease management. Real-time detection of infectious diseases such as influenza, dengue or COVID-19 enables earlier quarantine decisions and reduces transmission [12]. Mechanistically, real-time biosensors require fast electron transfer, optimized surface chemistry and efficient mass transport within the sensor interface. Materials such as graphene, carbon nanotubes and conductive polymers enhance transduction efficiency by improving charge mobility and biomolecule immobilization [13].

5. Biomarkers for Disease Detection

Disease biomarkers span nucleic acids, proteins, antigens, metabolites and exosomes. Molecular biomarkers provide a unique diagnostic signature, making them ideal for biosensing applications. For infectious diseases, antigenic proteins and viral RNA sequences serve as critical detection targets [14]. Cancer diagnostics increasingly rely on circulating tumor DNA, microRNAs and tumor-associated antigens [15]. Metabolic diseases use enzymatic biomarkers such as lactate, cholesterol and glucose. Biosensors that target inflammatory cytokines like IL-6 and TNF- α are being explored for sepsis detection and early inflammatory response monitoring [16]. Advances in synthetic biology have enabled engineered receptors with superior affinity, while molecular imprinting offers customizable binding sites for small-molecule biomarkers.

6. Nanomaterials and Microfabrication

Nanomaterials significantly enhance biosensor performance by increasing surface area, conductivity and catalytic activity. Graphene-based sensors, for example, achieve rapid electron transfer and exceptional sensitivity for disease biomarkers [17]. Gold nanoparticles enable plasmonic detection and fluorescence quenching, improving sensitivity in optical biosensors [18]. Microfabrication techniques, including lithography and 3D nano-printing, enable miniaturized lab-on-chip platforms. These microfluidic biosensors integrate sample preprocessing and detection, reducing assay time and reagent consumption [19]. Lab-on-a-chip systems have shown great promise for point-of-care diagnostics in low-resource settings.

7. Wearable and Implantable Biosensing Platforms

Wearable biosensors integrated into skin patches, textiles or wristbands can continuously monitor biomarkers in sweat, saliva or interstitial fluid. Flexible electronics and bioadhesive materials enhance comfort and signal fidelity [20]. Implantable biosensors are vital for chronic disease management, particularly for continuous glucose monitoring in diabetes. Long-term implantation requires biocompatibility, foreign-body-response minimization and stable calibration [21]. The coupling of wearable sensors with smartphone applications allows remote monitoring for cardiac risk detection, metabolic disorders and stress biomarkers.

8. Biosensors and Digital Health Integration

The convergence of biosensors with digital technologies, including AI, big data analytics and IoT, has transformed diagnostic workflows. Machine learning algorithms enhance signal interpretation, noise reduction and anomaly detection [22]. Biosensor-linked IoT networks enable real-time outbreak surveillance and rapid triage during epidemics [23]. Digital twins, which replicate patient physiology in silico, can incorporate biosensor data for predictive modeling and personalized treatment optimization. Such integration represents the future of precision diagnostics.

9. Current Challenges

Key challenges include biological instability, environmental interference, nanomaterial toxicity, signal drift and reproducibility issues. Manufacturing and distribution remain problematic in low-income regions. Regulatory approval pathways for biosensors, particularly wearable and implantable systems, are still evolving. Additionally, data privacy remains a major concern when biosensors interface with cloud-based platforms [24].

10. Future Directions

Future research will likely focus on multiplexed biosensing platforms capable of detecting multiple biomarkers simultaneously. CRISPR-based biosensors are expected to expand into early cancer detection and pharmacogenomics. The integration of biosensors into bioelectronic medicine, where electrical modulation is used to influence physiological pathways, represents a transformative frontier. Personalized, AI-driven biosensor ecosystems may soon allow at-home disease prediction with clinical-grade accuracy.

11. Conclusion

Biosensors have evolved into indispensable tools for real-time disease detection, offering unparalleled speed, accuracy and accessibility. Advances in nanotechnology, microfluidics, synthetic biology and digital health have expanded their clinical potential. Despite challenges in stability, regulation and deployment, the integration of biosensors into healthcare systems promises to revolutionize diagnostics, support precision medicine and enhance global health preparedness.

References

1. A. H. M. Imam, et al., "Point-of-care biosensors for infectious diseases," *Biosensors and Bioelectronics*, vol. 181, 2021.
2. S. Sharma and S. Byrne, "Real-time diagnostics and digital biosensing," *Nature Biotechnology*, vol. 39, 2021.
3. M. P. Rani et al., "Advances in biorecognition elements for biosensors," *Analytical Chemistry*, 2020.
4. L. C. Clark and C. Lyons, "Electrode systems for continuous monitoring in cardiovascular surgery," *Annals of the New York Academy of Sciences*, 1962.
5. J. Homola, "Surface plasmon resonance sensors for detection of chemical and biological species," *Chemical Reviews*, 2008.
6. M. S. Wicaksono et al., "Wearable IoT biosensing devices," *IEEE Sensors Journal*, 2020.
7. R. M. Reynolds, "Electrochemical glucose sensors," *IEEE Rev. Biomed. Eng.*, 2019.
8. N. C. Lindquist et al., "SERS for viral detection," *Nano Letters*, 2018.
9. J. Fritz, "Cantilever-based biosensors," *Science*, 2000.
10. J. S. Gootenberg et al., "CRISPR-Cas13a SHERLOCK detection," *Science*, 2017.
11. J. Wang, "Real-time biosensing technologies," *Biosensors and Bioelectronics*, 2021.
12. C. Yang et al., "Rapid sensors for COVID-19 detection," *ACS Nano*, 2020.
13. A. K. Geim, "Graphene-based biosensors," *Nature Materials*, 2016.
14. F. Li et al., "Viral RNA biosensing," *Analytical Chemistry*, 2020.
15. G. Schwarzenbach, "Circulating tumor DNA," *Nature Reviews Cancer*, 2011.
16. M. Cao et al., "Cytokine biosensing," *Biosensors*, 2022. "Nanomaterials for biomedical sensors," *Nature*, 2012. "Gold nanoparticle-based biosensors," *ACS Applied Materials & Interfaces*, 2019.
17. A. Manz et al., "Microfluidic systems for diagnostics," *Lab on a Chip*, 2020.
18. J. Kim et al., "Wearable bioelectronics for personalized healthcare," *Science Translational Medicine*, 2019.

19. S. Hossain et al., “Implantable biosensor systems,” IEEE Trans. Biomed. Eng., 2020.
20. R. D. Brook et al., “AI-assisted biosensor analytics,” Nature Machine Intelligence, 2021.
21. M. Y. Kwan et al., “IoT-driven disease monitoring,” IEEE Internet of Things Journal, 2022.
22. E. R. Dougherty, “Regulatory challenges in biosensor deployment,” IEEE Rev. Biomed. Eng., 2018.



© 2024 by the authors. Open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license
<http://creativecommons.org/licenses/by/4.0/>